現代の左心室補助器の受容者における補助療法としてのメゼンキマ前駆体細胞

Deborah D Ascheim¹, Annetine C Gelijns², Daniel Goldstein²+25

• ¹From the Icahn School of Medicine at Mount Sinai, New York, NY (D.D.A., A.C.G., M.K.P., J.L., E.B., E.A.R.); Montefiore-Einstein Heart Center, Bronx, NY (D.G.); University of Texas, Houston (L.A.M.); Cleveland Clinic Foundation, Cleveland, OH (N.S., S.L.); University of Florida, Gainesville (C.T.K., A.S.); National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (N.O.J., W.C.T.-P., M.A.M.); Mesoblast Inc, New York, NY (D.S.); Texas Heart Institute, Houston (D.A.T.); University of Pennsylvania, Philadelphia (J.E.R.); Duke University, Durham, NC (C.M., J.G.R.); Baylor Health Care System, Dallas, TX (T.D., E.E.); Minneapolis Heart Institute Foundation, Minneapolis, MN (B.S., D.F.); Mayo Clinic, Rochester, MN (R.S.); Brigham and Women's Hospital, Boston, MA (P.T.O.); Columbia University Medical Center, New York, NY (Y.N.); and Stanford University, Stanford, CA (Y.J.W.). deborah.ascheim@mssm.edu.+1